George:
VRII.... the purchasing was ongoing into the story unfolding in Peru, wasn't it? Acquisition in the face of justifiable weakness?
The MCDE royalties are single digit. Assume that Daiichi is 6%, and you'll be very close if not dead-on. Sure Lampert can get info relating to royalty levels. It's in a company's interest to help certain analysts, to prevent the analysts from making fools of themselves. So, you find a good (competent!) analyst or consultant that is a friend of the company, and you find the approximate royalty rate. I'm certain that Lampert and his advisors get some direct guidance.
How this thread is supposed to work? I'd like us to crawl inside the skin of those who move money through the industry, to understand who makes money and how. Lampert seems to focus on the long-term interest of patients, on excellence in science. Paramount/Aries/Rosenwald seem to focus, IMO, on the preservation of capital and the potential to bump into big money. They bumped into it with Interneuron, but, as we know, that story came apart at the seams.
The convergence of Lampert and Aries on RGEN is going to be fun to watch.
Here's fun news, moving money.......
biz.yahoo.com
I usually avoid Rosenwald-type companies like the plague. However, I've recently invested in two of them. Can anybody guess which two?
Cheers! Rick |
